Recent studies have centered on the convergence of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and dopamine neurotransmission. While GCGR stimulators are widely employed for treating type 2 T2DM, their potential consequences on motivation circuits, specifically influenced by dopaminergi